Antioxidant and Vasodilator Composition for cCMV Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for congenital cytomegalovirus (cCMV)-induced hearing loss are ineffective, and there is a need for novel agents to prevent progressive hearing loss in infected individuals, as existing therapies like ganciclovir have significant side effects and no vaccine is available.
Innovation Solution
A composition comprising biologically effective amounts of vitamin A, vitamin E, vitamin C, a vasodilator such as magnesium, and optionally withanolide or resveratrol, which work through different biological mechanisms to reduce free radicals and improve blood flow to the inner ear, thereby treating and preventing cCMV-induced hearing loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ganciclovir or valganciclovir is used to treat cCMV-induced hearing loss, then the progressive nature of hearing loss is attenuated, but neutropenia, potential infertility and teratogenesis occur
Solution Approach 1:
The patent employs a combination of vitamins (A, C, E) and antioxidants that are naturally occurring, safe, and can be administered repeatedly without accumulating toxic effects. These short-acting nutritional compounds replace the long-term toxic exposure to ganciclovir, providing continuous protection without persistent side effects.
Solution Approach 2:
The patent converts the harmful oxidative stress and vascular damage caused by cCMV into a treatable condition by using antioxidants and vasodilators. The same free radicals that cause damage are targeted and neutralized by antioxidant compounds, turning the harmful mechanism into a pathway for treatment.
2Object-affected harmful factors
If no treatment is provided for cCMV-induced hearing loss, then side effects are avoided, but hearing loss progresses and permanent disabilities develop
Solution Approach 1:
The patent enables preliminary treatment with antioxidants and vasodilators that can be administered early in the course of cCMV infection to prevent the progression of hearing loss before permanent damage occurs. This preliminary action addresses the infection's effects on the inner ear before irreversible sensorineural damage sets in.
Solution Approach 2:
The patent introduces intermediary compounds (vitamins and antioxidants) that mediate between the cCMV infection and the inner ear structures. These intermediaries protect the hair cells and vascular structures from direct viral damage and oxidative stress without requiring direct antiviral action on the virus itself.
3Reliability
If a vaccine for cCMV is developed, then prevention of infection is achieved, but currently no vaccine is available leaving 20,000 neonates infected annually
Solution Approach 1:
The patent provides preliminary protective action through antioxidant and vasodilator therapy that can be administered to at-risk infants even in the absence of a vaccine. This preliminary treatment creates a protective effect against hearing loss progression that would otherwise occur following cCMV infection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces oxidative stress and vascular damage in the inner ear, offering an additive effect greater than the sum of individual components, thereby treating and preventing cCMV-induced hearing loss, with potential for use as both a treatment and prophylaxis.
Implementation Method 1
the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C... to reduce free radicals and improve blood flow
Implementation Method 2
a vasodilator comprising magnesium... to reduce free radicals and improve blood flow to the inner ear
Data Source
AI summary
A method of treating congenital cytomegalovirus (cCMV) induced hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.